阿莱克提尼布在早期无细胞淋巴瘤激酶阳性非小细胞肺癌中的治疗:目前的证据和未来的挑战
Diego Luigi Cortinovis1,2, Alessandro Leonetti3, Alessandro Morabito4
1Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Cancers
|July 27, 2024
概括
辅助性阿列克提尼布现在是可切除的形淋巴瘤激酶阳性肺癌的标准治疗方法,显著改善了无病生存率. 周围的alectinib也正在研究未来的治疗选择.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 向疗法已经改变了先进的非小细胞肺癌治疗.
- 这些疗法对改善可切除肺癌的结果有前途.
研究的目的:
- 为了评估辅助性alectinib在可切除的阿纳普拉斯性淋巴瘤激酶阳性非小细胞肺癌中的临床益处.
- 为这种患者群体建立一个新的护理标准.
主要方法:
- ALINA试验将辅助性alectinib与标准化疗进行了比较.
- 第二阶段试验 (ALNEO,NAUTIKA1) 正在研究术后的alectinib治疗.
主要成果:
- ALINA试验达到了其主要终点,显示了无病生存2年的显著增加.
- 患有IB-IIIA阶段疾病的无细胞淋巴瘤激酶阳性患者从辅助性alectinib中受益.
- 关于外科手术期间使用alectinib的发表病例报告令人鼓舞.
结论:
- 辅助性alectinib是治疗可切除的阿纳普拉斯性淋巴瘤激酶阳性肺癌的新标准.
- 阿莱克提尼布很快可能会在外科手术期间的治疗环境中使用.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K